|Bid||4.90 x 2100|
|Ask||4.95 x 700|
|Day's Range||4.86 - 5.00|
|52 Week Range||3.75 - 8.61|
|PE Ratio (TTM)||27.22|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.33|
On a per-share basis, the Ness Ziona, Israel-based company said it had net income of 16 cents. The biopharmaceutical posted revenue of $35.7 million in the period. For the year, the company reported net ...
Total Revenues for Fiscal 2017 were $102.8 Million, up 33% Over Fiscal 2016; Exceeded Full-Year Revenue Guidance of $100 Million Full-Year Proprietary Products Revenues up 42% Year-Over-Year Gross Profit ...
REHOVOT, Israel, Feb. 02, 2018-- Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today announced that it will release financial results for the fiscal year ended ...
Kamada’ s IV AAT Demonstrated Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment, Consistent with Previously Observed Results in Other Indications. Next Interim ...
Study will be Co-Funded by Mount Sinai and Kamada, and will Utilize Biomarkers Developed by Mount Sinai Acute GvHD International Consortium to Identify Patients at High-Risk. Kamada Received Exclusive ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Kamada Ltd. Here are 5 ETFs with the largest exposure to KMDA-US. Comparing the performance and risk of Kamada Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Kamada Ltd. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Kamada Ltd. – Anthera Pharmaceuticals, Inc., Compugen Ltd. and Vertex Pharmaceuticals Incorporated (ANTH-US, CGEN-US and VRTX-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)
The Ness Ziona, Israel-based company said it had a loss of 1 cent per share. Earnings, adjusted for stock option expense, were less than 1 cent on a per-share basis. The biopharmaceutical posted revenue ...
Kamada Ltd. (KMDA) and partner Kedrion Biopharma and announced that FDA has approved Kedrab [rabies immune globulin (Human)] for post-exposure prophylaxis against rabies infection.
Research Desk Line-up: 22nd Century Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Kamada ...
Kedrion Biopharma and Kamada Ltd. , two leading human-derived protein therapeutics companies, today announced that KEDRAB™ has received U.S.